N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C24H20ClFN4O4
Molecular Weight	482.891
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE

Structure Search

SMILES

OCC(O)C(=O)NC1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1

InChI

InChIKey=NWFMVILQVXZATJ-UHFFFAOYSA-N

InChI=1S/C24H20ClFN4O4/c25-19-10-17(5-7-22(19)34-12-14-2-1-3-15(26)8-14)29-23-18-9-16(30-24(33)21(32)11-31)4-6-20(18)27-13-28-23/h1-10,13,21,31-32H,11-12H2,(H,30,33)(H,27,28,29)

HIDE SMILES / InChI

Molecular Formula	C24H20ClFN4O4
Molecular Weight	482.891
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:11:15 GMT 2023` Edited by `admin` on `Sat Dec 16 16:11:15 GMT 2023`
Record UNII	GGA6DL772Q
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE

Systematic Name

English

ALLITINIB METABOLITE M10

Common Name

English

PROPANAMIDE, N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXY-

Systematic Name

English

Code System Code Type Description

CAS

1469980-18-4

Created by admin on Sat Dec 16 16:11:16 GMT 2023 , Edited by admin on Sat Dec 16 16:11:16 GMT 2023

PRIMARY

PUBCHEM

156028094

Created by admin on Sat Dec 16 16:11:16 GMT 2023 , Edited by admin on Sat Dec 16 16:11:16 GMT 2023

PRIMARY

FDA UNII

GGA6DL772Q

Created by admin on Sat Dec 16 16:11:16 GMT 2023 , Edited by admin on Sat Dec 16 16:11:16 GMT 2023

PRIMARY

Related Record Type Details


					RO03J093CP

EPIDERMAL GROWTH FACTOR RECEPTOR

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					7J9Y28299R

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2

TARGET->WEAK INHIBITOR

Qualification:

IC50

Amount:

Related Record Type Details


					CX0M5RO7CY

ALLITINIB

PARENT -> METABOLITE

Qualification:

FECAL; PLASMA; URINE

Name	Property Type	Parameters
Biological Half-life	PHARMACOKINETIC	IN CANCER PATIENTS THREE TIMES A DAY FOR 21 DAYS ORAL ADMINISTRATION AT DAY 24

Tmax	PHARMACOKINETIC	ORAL ADMINISTRATION AT DAY 1 THREE TIMES A DAY IN CANCER PATIENTS

Tmax	PHARMACOKINETIC	ORAL ADMINISTRATION THREE TIMES A DAY FOR 21 DAYS AT DAY 24 IN CANCER PATIENTS

Biological Half-life	PHARMACOKINETIC	ORAL ADMINISTRATION IN CANCER PATIENTS THREE TIMES A DAY AT DAY 1